{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:02:58Z","timestamp":1760576578232,"version":"build-2065373602"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021806","name":"Hsinchu Science Park","doi-asserted-by":"publisher","award":["NSTC 113-2320-B-002-058"],"award-info":[{"award-number":["NSTC 113-2320-B-002-058"]}],"id":[{"id":"10.13039\/501100021806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108917","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:10:02Z","timestamp":1756307402000},"page":"108917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent"],"prefix":"10.1016","volume":"165","author":[{"given":"Hsuan-Chun","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tse-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Yu","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Hsuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sian-Siou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao-Hsia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Ling","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jih-Hwa","family":"Guh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108917_bb0005","first-page":"229","article-title":"Global cancer statistics, 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.108917_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2015","key":"10.1016\/j.bioorg.2025.108917_bb0015","first-page":"1243","article-title":"World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"W.D. Travis, E. Brambilla, A.G. Nicholson, Y. Yatabe, J.H. M. Austin, M.B. Beasley, L.R. Chirieac, S. Dacic, E. Duhig, D.B. Flieder, K. Geisinger, F.R. Hirsch, Y. Ishikawa, K.M. Kerr, M. Noguchi, G. Pelosi, C.A. Powell, M.S. Tsao, I. Wistuba, WHO Panel, The","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0020","doi-asserted-by":"crossref","unstructured":"A.G. Nicholson, M.S. Tsao, M.B. Beasley, A.C. Borczuk, E. Brambilla, W.A. Cooper, S. Dacic, D. Jain, K.M. Kerr, S. Lantuejoul, M. Noguchi, M. Papotti, N. Rekhtman, G. Scagliotti, P. van Schil, L. Sholl, Y. Yatabe, A. Yoshida, W.D. Travis, The 2021 WHO classification of lung tumors: impact of advances since 2015. J. Thorac. Oncol. 17 (2022) 362\u2013387. Doi: https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003.","DOI":"10.1016\/j.jtho.2021.11.003"},{"key":"10.1016\/j.bioorg.2025.108917_bb0025","article-title":"Current treatments for non-small cell lung cancer","volume":"12","author":"Guo","year":"2002","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological Actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bioorg.2025.108917_bb0045","first-page":"37","article-title":"Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung Cancer: where are we now and what should we expect?","volume":"38","author":"Damaskos","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bioorg.2025.108917_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.960263","article-title":"Histone deacetylases modulate resistance to the therapy in lung cancer","volume":"13","author":"Contreras-Sanz\u00f3n","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.bioorg.2025.108917_bb0055","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108917_bb0060","doi-asserted-by":"crossref","first-page":"8107318","DOI":"10.1155\/2019\/8107318","article-title":"Current landscape of epigenetics in lung Cancer: focus on the mechanism and application","volume":"2019","author":"Shi","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mole Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0070","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.2147\/CMAR.S257188","article-title":"Review about Pembrolizumab in first-line treatment of advanced NSCLC: focus on KEYNOTE studies","volume":"12","author":"Qu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0075","first-page":"398","article-title":"Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review, Transl. Lung","volume":"13","author":"Bai","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104462","article-title":"Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs)","volume":"106","author":"Linciano","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20200","article-title":"Histone deacetylase inhibitors (HDACIs). Structure\u2014activity relationships: history and new QSAR perspectives","volume":"32","author":"Pontiki","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.108917_bb0090","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6603464","article-title":"Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma","volume":"95","author":"O'Connor","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of Panobinostat","volume":"57","author":"Van Veggel","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2025.108917_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155216634178","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"23","author":"Campbell","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bioorg.2025.108917_bb0105","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","article-title":"A phase 2 study of vorinostat in acute myeloid leukemia","volume":"94","author":"Schaefer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.108917_bb0110","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2017.172411","article-title":"Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.108917_bb0115","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","article-title":"A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer consortium study","volume":"55","author":"Kirschbaum","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2025.108917_bb0120","first-page":"292","article-title":"Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia, genes","volume":"7","author":"Li","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0125","article-title":"Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells","volume":"30","author":"Alqosaibi","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.108917_bb0130","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2017.12.030","article-title":"Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling","volume":"417","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108917_bb0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108917_bb0145","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0150","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.bmc.2005.04.002","article-title":"Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent","volume":"13","author":"Suzuki","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0155","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3390\/molecules26175151","article-title":"Non-Hydroxamate zinc-binding groups as warheads for histone deacetylases","volume":"26","author":"Fr\u00fchauf","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108917_bb0160","doi-asserted-by":"crossref","first-page":"13821","DOI":"10.1021\/acs.jmedchem.3c01345","article-title":"Difluoromethyl-1,3,4-oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6","volume":"66","author":"K\u00f6nig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117218","article-title":"Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies","volume":"178","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.108917_bb0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.chembiol.2014.12.015","article-title":"Identification of histone deacetylase inhibitors with Benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases","volume":"22","author":"Wang","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0175","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.108917_bb0180","first-page":"994","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate","volume":"6","author":"Riva","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005871","volume":"11","author":"Marquardt","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0190","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1158\/1535-7163.MCT-09-0629","article-title":"Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors","volume":"8","author":"Konsoula","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108917_bb0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11684-019-0694-8","article-title":"Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer","volume":"14","author":"Xu","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2025.108917_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696512","article-title":"Selective histone deacetylase inhibitor ACY-241 (Citarinostat) plus Nivolumab in advanced non-small cell lung Cancer: results from a phase Ib study","volume":"11","author":"Awad","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-023-03973-3","article-title":"HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2\/miR-130a-3p-dependent mechanism","volume":"21","author":"Cui","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.108917_bb0210","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.20892\/j.issn.2095-3941.2021.0130","article-title":"The HDAC inhibitor GCJ-490A suppresses c-met expression through IKK\u03b1 and overcomes gefitinib resistance in non-small cell lung cancer","volume":"19","author":"He","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bioorg.2025.108917_bb0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tranon.2019.11.001","article-title":"Inhibition of HDAC6 attenuates tumor growth of non-small cell lung Cancer","volume":"13","author":"Deskin","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0220","article-title":"Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung Cancer cells","volume":"7","author":"Wang","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2025.108917_bb0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12032-016-0765-5","article-title":"HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells","volume":"33","author":"Wang","year":"2016","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0230","doi-asserted-by":"crossref","unstructured":"K. Yue, M. Qin, C. Huang, C. James Chou, Y. Jiang, X. Li, Comparison of three zinc binding groups for HDAC inhibitors \u2013 a potency, selectivity and enzymatic kinetics study, bioorg. Med.I Chem. Lett. 70 (2022) 128797. Doi: https:\/\/doi.org\/10.1016\/j.bmcl.2022.128797.","DOI":"10.1016\/j.bmcl.2022.128797"},{"key":"10.1016\/j.bioorg.2025.108917_bb0235","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: lessons from non-Hydroxamic acid Vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0240","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acs.jmedchem.8b01590","article-title":"Quinazolin-2,4-dione-based Hydroxamic acids as selective histone Deacetylase-6 inhibitors for treatment of non-small cell lung Cancer","volume":"62","author":"Yu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0245","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bcp.2019.03.023","article-title":"High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma","volume":"163","author":"Liu","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0250","doi-asserted-by":"crossref","first-page":"12140","DOI":"10.1021\/acs.jmedchem.2c00853","article-title":"First-in-class hydrazide-based HDAC6 selective inhibitor with potent Oral anti-inflammatory activity by attenuating NLRP3 Inflammasome activation","volume":"65","author":"Yue","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0255","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph18040577","article-title":"Drug discovery for histone deacetylase inhibition: past, present and future of zinc-binding groups","volume":"18","author":"Pires","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2025.108917_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116042","article-title":"Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition","volume":"265","author":"Tseng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0265","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1016\/j.bmcl.2016.08.073","article-title":"Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy","volume":"26","author":"Jiao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108917_bb0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cmdc.201200076","article-title":"Hydroxamic acids as potent inhibitors of Fe(II) and Mn(II) E. Coli methionine aminopeptidase: biological activities and X-ray structures of oxazole hydroxamate-EcMetAP-Mn complexes","volume":"7","author":"Huguet","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.108917_bb0275","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/S0960-894X(02)00754-0","article-title":"Trifluoromethyl ketones as inhibitors of histone deacetylase","volume":"12","author":"Frey","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108917_bb0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1039\/C5MD00451A","article-title":"A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action","volume":"7","author":"Madsen","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.bioorg.2025.108917_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114807","article-title":"Rational design of metabolically stable HDAC inhibitors: an overhaul of trifluoromethyl ketones","volume":"244","author":"Riddhidev","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0290","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1099\/jgv.0.000716","article-title":"Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells","volume":"98","author":"Kobayashi","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0295","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1021\/acs.jmedchem.3c01422","article-title":"N-(2-Aminophenyl)-benzamide inhibitors of class I HDAC enzymes with Antiproliferative and Antifibrotic activity","volume":"66","author":"Gerokonstantis","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0300","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.jmb.2014.03.007","article-title":"Molecular basis for the Antiparasitic activity of a Mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen Schistosoma mansoni","volume":"426","author":"Stolfa","year":"2014","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112887","article-title":"Mercaptoacetamide: a promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors","volume":"209","author":"Tavares","year":"2021","journal-title":"Eur. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0310","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12935-016-0315-4","article-title":"Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa","volume":"16","author":"Murad","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2025.108917_bb0315","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.108917_bb0320","first-page":"513","article-title":"The role of the ubiquitously expressed transcription factor Sp1 in tissue-specific transcriptional regulation and in disease","volume":"89","author":"O\u2019Connor","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.bioorg.2025.108917_bb0325","article-title":"The role of Sp1 in the detection and elimination of cells with persistent DNA strand breaks. NAR","volume":"2","author":"Loshchenova","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108917_bb0330","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/cells12081169","article-title":"Noncanonical roles of RAD51","volume":"12","author":"Thomas","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.108917_bb0335","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0340","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"23","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108917_bb0345","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0350","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-024-01927-9","article-title":"Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.108917_bb0355","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1568011054222364","article-title":"Etoposide, topoisomerase II and cancer","volume":"5","author":"Baldwin","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/j.bioorg.2025.108917_bb0360","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41589-022-01235-9","article-title":"Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II","volume":"19","author":"Le","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14796694.1.1.7","article-title":"Role of gemcitabine in cancer therapy","volume":"1","author":"Toschi","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2025.108917_bb0370","first-page":"209","article-title":"Gemcitabine for the treatment of advanced nonsmall cell lung cancer","volume":"2","author":"Toschi","year":"2009","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bioorg.2025.108917_bb0375","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3892\/or.2013.2767","article-title":"Etoposide induces apoptosis via the mitochondrial- and caspase-dependent pathways and in non-cancer stem cells in Panc-1 pancreatic cancer cells","volume":"30","author":"Zhang","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2025.108917_bb0380","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/jcmm.12444","article-title":"Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis","volume":"19","author":"Guo","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bioorg.2025.108917_bb0385","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0390","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108917_bb0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2010.04.014","article-title":"HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells","volume":"296","author":"Lee","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108917_bb0400","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","article-title":"Cellular response to etoposide treatment","volume":"252","author":"Montecucco","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108917_bb0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0415","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.108917_bb0420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mrfmmm.2013.07.007","article-title":"Double strand break repair functions of histone H2AX","volume":"750","author":"Scully","year":"2013","journal-title":"Mut. Res."},{"key":"10.1016\/j.bioorg.2025.108917_bb0425","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2741\/3652","article-title":"Replication protein a: directing traffic at the intersection of replication and repair","volume":"15","author":"Oakley","year":"2010","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.bioorg.2025.108917_bb0430","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","article-title":"Nonhomologous DNA end-joining for repair of DNA double-strand breaks","volume":"293","author":"Pannunzio","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108917_bb0435","doi-asserted-by":"crossref","unstructured":"L. Di, E.H. Kerns, Chapter 7 - Solubility. In Drug-Like Properties (Second Edition), L. Di, E.H. Kerns, Eds.; Academic Press, (2016) 61\u201393.","DOI":"10.1016\/B978-0-12-801076-1.00007-1"},{"key":"10.1016\/j.bioorg.2025.108917_bb0440","doi-asserted-by":"crossref","unstructured":"K. Sch\u00f6ffski, D. Strohm, Karl Fischer moisture determination, in: Encyclopedia Anal. Chem. John Wiley Sons Ltd, (2006), doi: https:\/\/doi.org\/10.1002\/9780470027318.a8102.","DOI":"10.1002\/9780470027318.a8102"},{"key":"10.1016\/j.bioorg.2025.108917_bb0445","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cjce.25295","article-title":"Experimental methods in chemical engineering: Karl Fischer titration","volume":"102","author":"Rivera-Quintero","year":"2024","journal-title":"Can. J. Chem. Eng."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:23:47Z","timestamp":1760559827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":89,"alternative-id":["S0045206825007977"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108917","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108917"}}